Drugs / CKD-352
last change May 2021 re-read 2 minutes ago

CKD-352

Developed for
dry eye syndrome
Investigated by
Chong Kun Dang Pharmaceutical

Trials 1 · a red edge is where a trial was stopped

202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04548427 Sep 2020 → May 2021 dry eye syndrome Chong Kun Dang Pharmaceutical Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CKD-352 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04548427
Route Other “Eye Drop” NCT04548427